ENTITY
Sino Biopharmaceutical

Sino Biopharmaceutical (1177 HK)

367
Analysis
Health Care • Hong Kong
Sino Biopharmaceutical is a leading, innovation-driven pharmaceutical conglomerate in China, focusing on the research, development, manufacturing, and sale of pharmaceutical products. The company specializes in therapeutic areas such as oncology, hepatology, respiratory, and cardiovascular diseases, offering both modernized Chinese and Western medicines. It was founded in 2000 and is headquartered in Wanchai, Hong Kong.
more
Exchange Announcement • 14 Oct 2026 18:20

Voluntary Announcement - Latest Research Results On Tq-A3334 "Tlr7 Agonist" And Bepirovirsen "Aso" To Be Presented At 2026 Aasld

Exchange Announcement • 14 Oct 2026 16:27

Next Day Disclosure Return

Exchange Announcement • 13 Oct 2026 16:55

Next Day Disclosure Return

Exchange Announcement • 08 Oct 2026 17:30

Voluntary Announcement - Completion Of All Subjects Enrollment In The Phase Iii Registrational Clinical Trial Of Tqc3721 Inhalation Suspension "Pde3/4 Inhibitor"

Exchange Announcement • 28 Sep 2026 16:45

Voluntary Announcement - Enter Into Strategic Biosimilars Partnership With Stada

x